Publications by authors named "Richard Colonno"

Claim this Profile
S
Safety, pharmacokinetics and antiviral activity of ABI-H2158, a hepatitis B virus core inhibitor: A randomized, placebo-controlled phase 1 study.
Kosh Agarwal, Jia Xu, Edward J Gane, Tuan T Nguyen, Yanhua Ding, Richard Colonno

J Viral Hepat· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a sensitive, multi-assay platform to monitor low levels of HBV DNA and pgRNA in patients with chronic hepatitis B virus infection.
Ran Yan, Dawei Cai, Lea Ouyang, Richard Colonno, Qi Huang

J Virol Methods· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical characterization of ABI-H2158, an HBV core inhibitor with dual mechanisms of action.
Ran Yan, Dawei Cai, Yuhua Zong, Lida Guo, Yi Zhou, Richard Colonno

Antiviral Res· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.
Mark S Sulkowski, Kosh Agarwal, Xiaoli Ma, Tuan T Nguyen, Eugene R Schiff, Richard Colonno

J Hepatol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection.
Man-Fung Yuen, Kosh Agarwal, Xiaoli Ma, Tuan T Nguyen, Eugene R Schiff, Richard Colonno

J Hepatol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients.
Qi Huang, Bin Zhou, Dawei Cai, Yuhua Zong, Yaobo Wu, Richard Colonno

Hepatology· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731.
Qi Huang, Dawei Cai, Ran Yan, Lichun Li, Yuhua Zong, Richard Colonno

Antimicrob Agents Chemother· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
Man-Fung Yuen, Kosh Agarwal, Edward J Gane, Christian Schwabe, Sang Hoon Ahn, Richard Colonno

Lancet Gastroenterol Hepatol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
Tao Wang, Yasu Ueda, Zhongxing Zhang, Zhiwei Yin, John Matiskella, Richard J Colonno

J Med Chem· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold.
Min Zhong, Eric Peng, Ningwu Huang, Qi Huang, Anja Huq, Richard Colonno

Bioorg Med Chem Lett· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4.
Gamal Esmat, Tamer Elbaz, Maissa El Raziky, Asmaa Gomaa, Mahmoud Abouelkhair, Richard Colonno

J Hepatol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound.
Jie Wang, Tao Shen, Xiangbo Huang, G Renuka Kumar, Xiangmei Chen, Richard Colonno

J Hepatol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor.
Min Zhong, Eric Peng, Ningwu Huang, Qi Huang, Anja Huq, Richard Colonno

Bioorg Med Chem Lett· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of functionalized bisimidazoles bearing cyclic aliphatic-phenyl motifs as HCV NS5A inhibitors.
Min Zhong, Eric Peng, Ningwu Huang, Qi Huang, Anja Huq, Richard Colonno

Bioorg Med Chem Lett· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent bisimidazole-based HCV NS5A inhibitors bearing annulated tricyclic motifs.
Min Zhong, Eric Peng, Ningwu Huang, Qi Huang, Anja Huq, Richard Colonno

Bioorg Med Chem Lett· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.
Julie A Lemm, Mengping Liu, Robert G Gentles, Min Ding, Stacey Voss, Richard Colonno

Antimicrob Agents Chemother· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase.
Robert G Gentles, Min Ding, John A Bender, Carl P Bergstrom, Katharine Grant-Young, Richard J Colonno

J Med Chem· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir.
Makonen Belema, Van N Nguyen, Carol Bachand, Dan H Deon, Jason T Goodrich, Richard J Colonno

J Med Chem· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
Paul M Scola, Alan Xiangdong Wang, Andrew C Good, Li-Qiang Sun, Keith D Combrink, Richard J Colonno

J Med Chem· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection.
Paul M Scola, Li-Qiang Sun, Alan Xiangdong Wang, Jie Chen, Ny Sin, Richard J Colonno

J Med Chem· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of 1-(4-benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1h-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-585248).
Alicia Regueiro-Ren, Qiufen M Xue, Jacob J Swidorski, Yi-Fei Gong, Marina Mathew, Richard J Colonno

J Med Chem· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).
Fiona McPhee, Amy K Sheaffer, Jacques Friborg, Dennis Hernandez, Paul Falk, Richard J Colonno

Antimicrob Agents Chemother· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 6. Preclinical and human pharmacokinetic profiling of BMS-663749, a phosphonooxymethyl prodrug of the HIV-1 attachment inhibitor 2-(4-benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043).
John F Kadow, Yasutsugu Ueda, Nicholas A Meanwell, Timothy P Connolly, Tao Wang, Richard J Colonno

J Med Chem· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043.
Nannan Zhou, Beata Nowicka-Sans, Sharon Zhang, Li Fan, Jie Fang, Richard Colonno

Antimicrob Agents Chemother· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects.
George J Hanna, Jacob Lalezari, James A Hellinger, David A Wohl, Richard Nettles, Richard Colonno

Antimicrob Agents Chemother· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis